Vildagliptin effects on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled, type 2 diabetes patients
Journal of Diabetes, 04/17/2012

Bunck MC et al. – One–year treatment with vildagliptin was not associated with changes in markers of bone resorption and calcium homeostasis in drug–naive patients with type 2 diabetes (T2D) and mild hyperglycemia.

• This is a single centre double blind, randomised clinical trail.
• Fifty–nine drug–naive patients with type 2 diabetes (T2D) were randomized to either one–year treatment with the DPP–4 inhibitor vildagliptin 100 mg (n=29) once daily or placebo (n=30).
• Patients received a standardized breakfast after the authors measured serum concentrations of cross–linked C–terminal telopeptide (s–CTx), a bone resorption marker influenced by food intake, before and after 50–weeks of treatment.

• Vildagliptin did not change postprandial s–CTx concentrations from pre–treatment (between group ratio 1.15±0.17; p=0.320).
• Fasting serum alkaline phosphatase, calcium, and phosphate also remained unaffected following one–year treatment.